Study on the efficacy of Taohong Siwu Decoction in treating Hepatitis B related fibrosis and its correlation with iron metabolism
- Conditions
- Hepatitis B related fibrosis
- Registration Number
- ITMCTR2100004426
- Lead Sponsor
- The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Aged 18 to 65 years, male or female.
(2) Meet the diagnostic criteria for liver fibrosis.
(3) Meet the diagnostic criteria of chronic hepatitis B and ALT < 3 x ULN.
(4) Comply with the diagnosis of blood stasis blocking collaterals syndrome in Chinese medicine.
(5) Voluntarily participate in the research, sign the informed consent form, and guarantee to receive follow-up.
(1) Have taken iron-containing drugs in the previous three months
(2) Liver fibrosis caused by other causes.
(3) Patients with other serious fatal liver diseases or complications, such as liver failure, septic shock, hepatic encephalopathy, hepatorenal syndrome, upper gastrointestinal bleeding.
(4) Severe diseases of the heart, kidney, brain, breathing, blood and other systems or other organs.
(5) Pregnant or lactating women or patients who have a pregnancy plan, patients with previous mental illness, epilepsy and other serious neurological or psychological diseases and alcoholic or drug addicts.
(6) Patients who have been participating in other drug clinical trials for nearly 3 months or received other Chinese medicine treatment.
(7) Patients with allergies or known allergies to the ingredients of this medicine.
(8) Patients have poor compliance.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method liver stiffness;
- Secondary Outcome Measures
Name Time Method aminin;Procollagen type III;Collage Type IV;ALT;AST;Hyaluronic acid;